Regression of Ductal carcinoma in situ after treatment with acupuncture

Journal of Alternative and Complementary Medicine

Volumn 19, Issue 11, 2013, Pages 911-915

  Dehen, Regina ^a  

^a OREGON COLLEGE OF ORIENTAL MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; CAFFEINE; CALCIUM; CHINESE DRUG; COMBIZYM; CYTOKERATIN; EOSIN; ESSENTIAL FATTY ACID; HERBACEOUS AGENT; LUI WEI DI HUANG WAN; MAGNESIUM; REN SHEN; RETINOL; SHEN LING BAI ZHU SAN; TURMERIC; UNCLASSIFIED DRUG; VITAMIN D; XIAO YAO WAN;

ACUPUNCTURE; ADULT; ALTERNATIVE MEDICINE; ARTICLE; BREAST BIOPSY; BREAST CALCIFICATION; BREAST DISCHARGE; CANCER REGRESSION; CASE REPORT; CHINESE HERB; CHRONIC INFLAMMATION; CLIMACTERIUM; COMEDO; DIET RESTRICTION; ECHOMAMMOGRAPHY; EPITHELIUM CELL; FAT NECROSIS; FEMALE; FOLLOW UP; GINSENG; HISTIOCYTE; HISTOPATHOLOGY; HOT FLUSH; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; MAMMOGRAPHY; MASTITIS; MEDITATION; METAPLASIA; MYOEPITHELIUM CELL; NUCLEAR MAGNETIC RESONANCE IMAGING; OPHIOCORDYCEPS; OUTCOME ASSESSMENT; PAPILLOMATOSIS; PRIORITY JOURNAL; REPEAT PROCEDURE; TREATMENT REFUSAL; WELLBEING;

ACUPUNCTURE THERAPY; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; MIDDLE AGED;

EID: 84888098052     PISSN: 10755535     EISSN: 15577708     Source Type: Journal    
DOI: 10.1089/acm.2012.0696     Document Type: Article

References (36)

1. Allegra CJ, Aberle DR, Ganschow P, et al. National Institutes of Health State-of-the-Science Conference statement: Diagnosis and management of ductal carcinoma in situ September 22-24, 2009. J Natl Cancer Inst 2010;102:161-169
2. Evans AJ, Pinder SE, Ellis IO, Wilson AR. Screen detected ductal carcinoma in situ (DCIS): overdiagnosis or an obligate precursor of invasive disease? J Med Screen 2001;8:149-151 (Pubitemid 32929841)
3. Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst 2010;102:170-178
4. Welch HG, Woloshin S, Schwartz LM. The sea of uncertainty surrounding ductal carcinoma in situ-the price of screening mammography. J Natl Cancer Inst 2008;100:228-229 (Pubitemid 351480539)
5. Nelson JN. DCIS prognostic markers: a few new candidates emerge. J Natl Cancer Inst 2010;102:588-590
6. Lari SA, Kuerer HM. Biological markers in DCIS and risk of breast recurrence: a systematic review. J Cancer 2011;2: 232-261
7. Collins LC, Tamimi RM, Baer HJ, et al. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses Health Study. Cancer 2005; 103:1778-1784 (Pubitemid 40563248)
8. Page DL, Dupont WD, Rogers LW, Jensen RA, Schuyler PA. Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer 1995;76:1197-2000
9. Eusebi V, Foschini MP, Cook MG, Berrino F, Azzopardi JG. Long-term follow-up of in situ carcinoma of the breast with special emphasis on clinging carcinoma. Semin Diagn Pathol 1989;6:165-173 (Pubitemid 19132527)
10. Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer and prostate cancer. JAMA 2009;302:1685-1692
11. Dillion MF, McDermott EW, Quinn CM, et al. Predictors of invasive disease when core biopsy demonstrates DCIS only. J Surg Oncol 2006;93:559-563 (Pubitemid 43806991)
12. Lagios MD, Margolin FR, Westdhal PR, Rose MR. Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognositic effect of nuclear grade on local recurrence. Cancer 1989;63:618-624 (Pubitemid 19050259)
13. Virnig BA, Shamilyan T, Tuttle TM, et al. Diagnosis and management of ductal carcinoma in situ (DCIS). Evidence Report/Technology Assessment No. 185. AHRQ Publication No. 09-E018. Bethesda, Maryland: Agency for Healthcare Research and Quality; 2009
14. Fisher B, Land S, Mamounas E, et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol 2001;28:400-418 (Pubitemid 32762083)
15. Solin LJ, McCormick B, Recht A, et al. Mammographically detected, clinically occult ductal carcinoma in situ treated with breast-conserving surgery and definitive breast irradiation. Cancer J Sci Am 1996;2:158-165
16. Fisher B, Anderson S, Redmond CK, et al. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1995;333:1456-1461
17. Silverstein MJ. Ductal carcinoma in situ of the breast: controversial issues. Oncologist 1998;3:94-103 (Pubitemid 28213171)
18. Alvarado R, Lari SA, Roses RE, et al. Biology, treatment, and outcome in very young and older women with DCIS. Ann Surg Oncol 201219:3777-3784
19. Partridge A, Adloff K, Blood E, et al. Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study. J Natl Cancer Inst 2008;100:243-251 (Pubitemid 351480537)
20. Lauzier S, Maunsell E, Levesque P, et al. Psychological distress and physical health in the year after diagnosis of DCIS or invasive breast cancer. Breast Cancer Res Treat 2010;120: 685-691
21. Kerlikowske K, Molinaro AM, Gauthier ML, et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst 2010;102: 627-637
22. Welch HG, Black WC. Using autopsy series to estimate the disease reservoir for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann Intern Med 1997;127:1023-1028 (Pubitemid 27516615)
23. Burnside E, Trentham-Dietz A, Kelcz F, Collins J. An example of breast cancer regression on imaging. Radiol Case Reports [Online] 2006;1:4
24. Tamimi RM, Baer HJ, Marotti J, et al. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res 2008;10:R67
25. Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001;96-102
26. Chen YY, DeVries S, Anderson J, et al. Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ. BMC Cancer 2009;9:285
27. Meyerson AF, Lessing JN, Itakura K, et al. Outcome of long term active surveillance for estrogen receptor-positive ductal carcinoma in situ. Breast 2011;20:529-533
28. Dai-zhao Z, Flaws B. The Treatment of Cancer by Integrated Chinese-Western Medicine. Boulder, Colorado: Blue Poppy Press; 1989
29. Watanabe T, Nakaya N, Kurashima K, et al. Constipation, laxative use and risk of colorectal cancer: the Miyagi Cohort Study. Eur J Cancer 2004;40:2109-2115 (Pubitemid 39165545)
30. Shemerovskii KA. Constipation-a risk factor for colorectal cancer. Klin Med (Mosk) 2005;83:60-64
31. Meng W, Cai SR, Zhou L, et al. Performance value of high risk factors in colorectal cancer screening in China. World J Gastroenterol 2009;15:6111-6116
32. Martin D. Physical activity benefits and risks on the gastrointestinal system. South Med J 2011;104:831-837
33. Simons CC, Schouten LJ, Weijenberg MP, et al. Bowel movement and constipation frequencies and the risk of colorectal cancer among men in the Netherlands Cohort Study on Diet and Cancer. Am J Epidemiol 2010;172:1404-1414
34. WuY. Practical Therapeutics of Traditional Chinese medicine. Taos, New Mexico: Redwing Book Company; 2009:434-437
35. Walker RA. Immunohistochemical markers as predictive tools for breast cancer. J Clin Pathol 2008;61:689-696 (Pubitemid 351859960)
36. Lerwill MF. Current practical applications of diagnostic immunohistochemistry in breast pathology. Am J Surg Pathol 2004;28:1076-1091.